LRMR — Larimar Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374690 ·
Last close
$4.28
Market Cap
$444.62M
52W High
$5.05
52W Low
$2.92
ADV30
2,757,829
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -31,117,000 | -29,613,000 | 208,511,000 | 177,913,000 | 50,478,000 |
| Dec 2025 | 0 | — | -64,018,000 | -62,498,000 | 145,842,000 | 85,412,000 | 67,757,000 |
| Sep 2025 | 0 | — | -49,499,000 | -47,712,000 | 187,350,000 | 90,140,000 | 48,312,000 |
| Jun 2025 | 0 | — | -27,792,000 | -26,182,000 | 149,988,000 | 20,587,000 | 30,134,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,275,000
Investing CF
$114,861,000
Financing CF
$173,201,000
CapEx
$-270,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.06
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,444,000
Inventory
—
Receivables
$791,000
ST Investments
$22,472,000
EBIT TTM
$-172,426,000
Pretax Income TTM
$-166,005,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,497,000 | -165,673,000 | 145,842,000 | 67,757,000 | — | -113,201,000 |
| Dec 2024 | 0 | -90,890,000 | -80,604,000 | 200,225,000 | 28,413,000 | — | -70,760,000 |
| Dec 2023 | 0 | -41,758,000 | -36,949,000 | 95,935,000 | 14,215,000 | — | -33,459,000 |
| Dec 2022 | 0 | -36,526,000 | -35,355,000 | 126,405,000 | 15,502,000 | — | -27,569,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $450.93M | $7.37 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $436.38M | $6.68 | — |
| EOLS | Evolus, Inc. | $435.30M | $6.61 | — |
| RZLT | Rezolute, Inc. | $457.39M | $4.75 | — |
| SLN | Silence Therapeutics plc | $429.36M | $9.09 | — |
News headlines (Yahoo Finance, 1h cache)
LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
2026-07-08 22:44 · Yahoo
Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
2026-07-03 13:13 · Yahoo
LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
2026-07-02 20:32 · Yahoo
Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
2026-06-29 14:00 · Yahoo
Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
2026-06-29 13:02 · Yahoo
Larimar Therapeutics Files First Module of BLA With US FDA for Nomlabofusp
2026-06-29 12:26 · Yahoo
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
2026-06-29 10:30 · Yahoo
Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia
2026-06-26 20:05 · Yahoo
Exploring 3 High Growth Tech Stocks in US Market
2026-06-15 11:39 · Yahoo
Exploring US High Growth Tech Stocks This May 2026
2026-05-15 11:38 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-07-08 16:05:03 | 2026-07-06 | Hamilton Thomas Edward | Dir | P - Purchase | 3.34 | 50000 | 166890 |